Jasper Therapeutics has announced the dosing of the first patient in a Phase 1 trial for Briquilimab, an antibody therapy targeting c-Kit (CD117) for lower-risk myelodysplastic syndromes (LR-MDS). The single-arm Phase 1 trial will evaluate briquilimab's safety and tolerability as a second-line therapy in subjects with LR-MDS. The trial will employ a dose escalation design to identify the optimal biologic dose and recommended Phase 2 dose of briquilimab monotherapy as a chronic therapeutic for LR-MDS patients with documented cytopenia such as red blood cell transfusion dependence, thrombocytopenia, or neutropenia.
Jasper Therapeutics is developing Briquilimab, a monoclonal antibody targeting c-Kit (CD117), as a therapeutic for chronic mast and stem cell diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA),